| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8668518 | Journal of Clinical Lipidology | 2018 | 17 Pages |
Abstract
Alirocumab significantly improved LDL-C, apolipoprotein B, non-HDL-C, lipoprotein (a), HDL-C, and total cholesterol in Asian patients. Alirocumab was generally well tolerated. These findings are consistent with ODYSSEY findings to date.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Kwang Kon MD, PhD, FACC, Chang Wook MD, PhD, FACC, Ting-Hsing MD, FACC, FESC, Ming-En MD, Chiung-Jen MD, Dong-Soo MD, PhD, Chong-Jin MD, PhD, Ivy MSc, Jianyong MD, Marie T. MD, MSc, Pi-Jung MD, MS, Chern-En MD, PhD, FACC,